Inspira Technologies (IINN) announced a pivotal commercial advancement. The Company has received official approval from the Medical Equipment Committee of Clalit Health Services. The approval enables the INSPIRA ART100 system for immediate procurement and operational use across Clalit’s extensive medical ecosystem. Key Highlights: Commercial Activation: The approval transitions the ART100 from regulatory clearance to active commercial availability within a network serving approximately 4.9 million members. Tier-1 Network Scale: Clalit operates 14 major hospitals and over 1,600 clinics. This approval effectively opens the door to one of the most sophisticated healthcare supply chains in the world. Validation of Clinical Value: The approval follows a rigorous technical and clinical review by the Professional Committee for Medical Equipment regarding Thoracic and Cardiac Surgery, signaling strong validation of the ART100’s safety and efficacy profile to other global health systems.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IINN:
- Inspira Technologies Wins Clalit HMO Vendor Status, Clearing Path for ART100 Rollout
- Inspira Technologies Raises $4.75 Million in At-the-Market Offering and Reprices Warrants
- Inspira Technologies prices 6.79M shares at 70c in registered direct offering
- Inspira Technologies Validates Standalone HYLA Blood Sensor, Targeting $50 Billion Heart-Lung Surgery Market
- Inspira Technologies announces validation of advanced blood labs of HYLA
